TABLE 1.
Baseline demographics and disease characteristics
| Baseline characteristics | All participants (N = 974) |
|---|---|
| Age, years | 61.6 ± 10.96 |
| Age group, years | |
| 18‐44 | 62 (6.4) |
| 45‐54 | 192 (19.7) |
| 55‐64 | 284 (29.2) |
| 65‐75 | 326 (33.5) |
| >75 | 110 (11.3) |
| Sex, male | 550 (56.5) |
| Baseline HbA1c, % | 11.3 ± 1.66 |
| Baseline HbA1c categories, % | |
| ≥9‐10 | 247 (25.4) |
| >10‐11 | 237 (24.3) |
| >11 | 490 (50.3) |
| BMI, kg/m2 | 30.9 ± 6.20 |
| BMI category, kg/m2 | |
| ≤25 | 152 (15.6) |
| >25‐30 (overweight) | 266 (27.3) |
| >30‐40 (obese) | 432 (44.4) |
| >40 (extremely obese) | 75 (7.7) |
| Missing and unknown | 49 (5.0) |
| Co‐morbidities | |
| Hypertension | 622 (63.9) |
| Dyslipidaemia | 220 (22.6) |
| Nephropathy (including CKD) | 201 (20.6) |
| Peripheral vascular disease | 64 (6.6) |
| Congestive heart failure | 61 (6.3) |
| Stroke | 41 (4.2) |
| Valvular heart disease | 25 (2.6) |
| Neuropathy | 16 (1.6) |
| Retinopathy | 11 (1.1) |
| OAD use in 12‐month preindex period | |
| Metformin | 960 (98.6) |
| DPP‐4 inhibitors | 493 (50.6) |
| Thiazolidinediones | 413 (42.4) |
| Sulphonylureas | 182 (18.7) |
| SGLT‐2 inhibitors | 5 (0.5) |
| Number of OADs used in 12‐month preindex period | |
| 2 | 534 (54.8) |
| ≥3 | 440 (45.2) |
| GP visits in 1 year preindex | 17.1 ± 10.5 |
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; DDP‐4, dipeptidyl peptidase‐4; GP, general practitioner; OAD, oral antihyperglycaemic drug; SD, standard deviation; SGLT‐2, sodium‐glucose linked co‐transporter‐2.
Data are n (%) or mean ± SD.